Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Spotlight on...osteoporosis

Following the World Osteoporosis Day last week, Siobhan Hallmark shares some information about the bone disease, as well as her thoughts on how pharma can improve the current situation for osteoporosis patients in the future. Osteoporosis occurs when the struts that make up the mesh like structure within bones become thin, causing...

Articles

Is collaboration key to the evolution of personalized medici...

Our latest interview is with Isabelle Tanneau, about the benefits, challenges and ethical issues facing pharma when it comes to personalized healthcare. As we enter a new era of healthcare, namely the personalized medicine era, it’s easy to question why pharma...

Articles

Interview with Kevin Hrusovsky part 3: the role of next gene...

Kevin Hrusovsky of PerkinElmer Inc. discusses the role of next generation sequencing in personalized medicine in the concluding part of his interview. Previously in this three-part interview Kevin shared with us the most recent exciting advances in the understanding of molecular interactions...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access